|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IGF2BP2 |
Gene summary for IGF2BP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IGF2BP2 | Gene ID | 10644 |
| Gene name | insulin like growth factor 2 mRNA binding protein 2 | |
| Gene Alias | IMP-2 | |
| Cytomap | 3q27.2 | |
| Gene Type | protein-coding | GO ID | GO:0001816 | UniProtAcc | Q9Y6M1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10644 | IGF2BP2 | CCI_1 | Human | Cervix | CC | 8.07e-18 | 1.95e+00 | 0.528 |
| 10644 | IGF2BP2 | CCI_2 | Human | Cervix | CC | 1.49e-25 | 2.21e+00 | 0.5249 |
| 10644 | IGF2BP2 | sample3 | Human | Cervix | CC | 1.32e-13 | 2.54e-01 | 0.1387 |
| 10644 | IGF2BP2 | H2 | Human | Cervix | HSIL_HPV | 4.26e-03 | 2.33e-01 | 0.0632 |
| 10644 | IGF2BP2 | T1 | Human | Cervix | CC | 2.72e-09 | 4.41e-01 | 0.0918 |
| 10644 | IGF2BP2 | T2 | Human | Cervix | CC | 1.68e-02 | 3.32e-01 | 0.0709 |
| 10644 | IGF2BP2 | T3 | Human | Cervix | CC | 7.74e-04 | 2.30e-01 | 0.1389 |
| 10644 | IGF2BP2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.96e-22 | -6.91e-01 | 0.0155 |
| 10644 | IGF2BP2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 3.34e-05 | -5.75e-01 | -0.1207 |
| 10644 | IGF2BP2 | HTA11_9341_2000001011 | Human | Colorectum | SER | 3.98e-04 | -7.71e-01 | -0.00410000000000005 |
| 10644 | IGF2BP2 | HTA11_7862_2000001011 | Human | Colorectum | AD | 7.94e-04 | -5.26e-01 | -0.0179 |
| 10644 | IGF2BP2 | HTA11_866_3004761011 | Human | Colorectum | AD | 2.54e-17 | -5.80e-01 | 0.096 |
| 10644 | IGF2BP2 | HTA11_8622_2000001021 | Human | Colorectum | SER | 4.66e-03 | -5.29e-01 | 0.0528 |
| 10644 | IGF2BP2 | HTA11_10623_2000001011 | Human | Colorectum | AD | 2.14e-02 | -4.33e-01 | -0.0177 |
| 10644 | IGF2BP2 | HTA11_10711_2000001011 | Human | Colorectum | AD | 6.75e-12 | -6.02e-01 | 0.0338 |
| 10644 | IGF2BP2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 3.22e-02 | -3.10e-01 | 0.0674 |
| 10644 | IGF2BP2 | HTA11_6818_2000001011 | Human | Colorectum | AD | 2.14e-04 | -4.91e-01 | 0.0112 |
| 10644 | IGF2BP2 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 2.30e-08 | -6.32e-01 | 0.2585 |
| 10644 | IGF2BP2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 5.17e-59 | -1.11e+00 | 0.3005 |
| 10644 | IGF2BP2 | F007 | Human | Colorectum | FAP | 8.81e-08 | -5.06e-01 | 0.1176 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000641710 | Cervix | CC | regulation of translation | 89/2311 | 468/18723 | 1.86e-05 | 3.46e-04 | 89 |
| GO:00512368 | Cervix | CC | establishment of RNA localization | 39/2311 | 166/18723 | 4.76e-05 | 7.25e-04 | 39 |
| GO:00506578 | Cervix | CC | nucleic acid transport | 38/2311 | 163/18723 | 7.06e-05 | 9.85e-04 | 38 |
| GO:00506588 | Cervix | CC | RNA transport | 38/2311 | 163/18723 | 7.06e-05 | 9.85e-04 | 38 |
| GO:000640310 | Cervix | CC | RNA localization | 43/2311 | 201/18723 | 2.00e-04 | 2.29e-03 | 43 |
| GO:00510284 | Cervix | CC | mRNA transport | 31/2311 | 130/18723 | 2.05e-04 | 2.33e-03 | 31 |
| GO:00159318 | Cervix | CC | nucleobase-containing compound transport | 43/2311 | 222/18723 | 1.72e-03 | 1.30e-02 | 43 |
| GO:000641715 | Cervix | HSIL_HPV | regulation of translation | 34/737 | 468/18723 | 4.66e-04 | 6.83e-03 | 34 |
| GO:0006417 | Colorectum | AD | regulation of translation | 141/3918 | 468/18723 | 1.32e-06 | 4.22e-05 | 141 |
| GO:0006403 | Colorectum | AD | RNA localization | 71/3918 | 201/18723 | 1.54e-06 | 4.76e-05 | 71 |
| GO:0051236 | Colorectum | AD | establishment of RNA localization | 58/3918 | 166/18723 | 1.95e-05 | 4.01e-04 | 58 |
| GO:0015931 | Colorectum | AD | nucleobase-containing compound transport | 73/3918 | 222/18723 | 2.02e-05 | 4.10e-04 | 73 |
| GO:0050657 | Colorectum | AD | nucleic acid transport | 57/3918 | 163/18723 | 2.22e-05 | 4.39e-04 | 57 |
| GO:0050658 | Colorectum | AD | RNA transport | 57/3918 | 163/18723 | 2.22e-05 | 4.39e-04 | 57 |
| GO:0051028 | Colorectum | AD | mRNA transport | 42/3918 | 130/18723 | 1.57e-03 | 1.32e-02 | 42 |
| GO:00064031 | Colorectum | SER | RNA localization | 53/2897 | 201/18723 | 4.51e-05 | 1.13e-03 | 53 |
| GO:00159311 | Colorectum | SER | nucleobase-containing compound transport | 54/2897 | 222/18723 | 3.65e-04 | 5.67e-03 | 54 |
| GO:00064171 | Colorectum | SER | regulation of translation | 100/2897 | 468/18723 | 3.76e-04 | 5.74e-03 | 100 |
| GO:00512361 | Colorectum | SER | establishment of RNA localization | 42/2897 | 166/18723 | 6.70e-04 | 8.96e-03 | 42 |
| GO:00506571 | Colorectum | SER | nucleic acid transport | 41/2897 | 163/18723 | 8.74e-04 | 1.06e-02 | 41 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IGF2BP2 | SNV | Missense_Mutation | rs140669105 | c.1124N>A | p.Ser375Asn | p.S375N | protein_coding | tolerated(0.8) | benign(0.003) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| IGF2BP2 | SNV | Missense_Mutation | c.1382G>A | p.Arg461Lys | p.R461K | protein_coding | tolerated(0.08) | benign(0.418) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR | ||
| IGF2BP2 | SNV | Missense_Mutation | c.113C>A | p.Ser38Tyr | p.S38Y | protein_coding | deleterious(0.02) | possibly_damaging(0.844) | TCGA-EW-A1PE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD | ||
| IGF2BP2 | insertion | Frame_Shift_Ins | novel | c.430_431insTTCAAGTTGTAGC | p.Glu144ValfsTer13 | p.E144Vfs*13 | protein_coding | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | |||
| IGF2BP2 | insertion | Frame_Shift_Ins | novel | c.844_845insTCCACCACAGTGTGTTGGGAGG | p.Pro282LeufsTer33 | p.P282Lfs*33 | protein_coding | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |||
| IGF2BP2 | insertion | Frame_Shift_Ins | novel | c.984_985insGAGAGATATATATCTACATACATACATGTGCA | p.Arg329GlufsTer16 | p.R329Efs*16 | protein_coding | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |||
| IGF2BP2 | deletion | Frame_Shift_Del | c.515delN | p.Pro172LeufsTer49 | p.P172Lfs*49 | protein_coding | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||||
| IGF2BP2 | deletion | Frame_Shift_Del | novel | c.1655delN | p.Pro552LeufsTer12 | p.P552Lfs*12 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | |||
| IGF2BP2 | SNV | Missense_Mutation | c.1382N>A | p.Arg461Lys | p.R461K | protein_coding | tolerated(0.08) | benign(0.418) | TCGA-Q1-A6DW-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | ||
| IGF2BP2 | SNV | Missense_Mutation | novel | c.126N>A | p.Phe42Leu | p.F42L | protein_coding | deleterious(0) | possibly_damaging(0.854) | TCGA-VS-A8EI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 10644 | IGF2BP2 | NA | repaglinide | REPAGLINIDE |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |